Drug Profile
Pramipexole - Chase Therapeutics
Alternative Names: CTC-413; CTC-501; Pramipexole ER; Pramipexole immediate release - Chase Therapeutics; Pramipexole IRLatest Information Update: 24 Feb 2022
Price :
$50
*
At a glance
- Originator Chase Therapeutics
- Class Antidepressants; Antiparkinsonians; Benzothiazoles; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Major depressive disorder; Parkinson's disease
Most Recent Events
- 24 Feb 2022 Phase II development is still ongoing for Major depressive disorders (Combination therapy) in USA
- 24 Feb 2022 Phase II development is still ongoing for Parkinson's disease (Combination therapy) in USA
- 22 Oct 2021 Pramipexole - Chase Therapeutics is available for licensing as of 22 Oct 2021. http://www.chasetherapeutics.com/partnering/